replicateBE: Average Bioequivalence with Expanding Limits (ABEL)

Performs comparative bioavailability calculations for Average Bioequivalence with Expanding Limits (ABEL). Implemented are 'Method A' and 'Method B' and the detection of outliers. If the design allows, assessment of the empiric Type I Error and iteratively adjusting alpha to control the consumer risk. Average Bioequivalence - optionally with a tighter (narrow therapeutic index drugs) or wider acceptance range (Gulf Cooperation Council, South Africa: Cmax) - is implemented as well.

Version: 1.0.15
Depends: R (≥ 3.5.0)
Imports: readxl (≥ 1.0.0), PowerTOST (≥ 1.3.3), lmerTest, nlme, pbkrtest, graphics, grDevices
Suggests: knitr, rmarkdown, testthat, devtools
Published: 2020-07-24
Author: Helmut Schütz ORCID iD [aut, cre], Michael Tomashevskiy [ctb], Detlew Labes ORCID iD [ctb]
Maintainer: Helmut Schütz <helmut.schuetz at>
License: GPL (≥ 3)
NeedsCompilation: no
Materials: README NEWS
In views: ClinicalTrials
CRAN checks: replicateBE results


Reference manual: replicateBE.pdf
Vignettes: replicateBE
Package source: replicateBE_1.0.15.tar.gz
Windows binaries: r-devel:, r-release:, r-oldrel:
macOS binaries: r-release: replicateBE_1.0.15.tgz, r-oldrel: replicateBE_1.0.15.tgz
Old sources: replicateBE archive


Please use the canonical form to link to this page.